Panacea Biotec Shares Rose Over 4% on Securing a Polio Vaccine Order from UNICEF

Panacea Biotec has received an additional order from UNICEF to supply 40 million doses of its bivalent oral polio vaccine (bopv). The order is valued at around $5.20 million (approximately ₹44 crore) and is scheduled for delivery in the third quarter of 2025.

Background and Continuation

This new order builds on an earlier agreement made in December 2024, where the company was awarded a contract to deliver 115 million bopv doses. The long-term contract between Panacea Biotec and UNICEF will be updated to include this new supply.

Key Details of the Order

The vaccines will be delivered internationally to meet UNICEF’s requirements. UNICEF will publicly share details about the supplier, vaccine type, contract duration and pricing on its official website. The full execution is planned for Q3 2025.

About the Companies 

Panacea Biotec is an Indian healthcare company that focuses on making vaccines, medicines and other health products. It has been involved in creating life-saving vaccines and has worked with global organisations to support public health. The company is known for its contribution to fighting diseases like polio and continues to grow through partnerships and international orders.

UNICEF (United Nations International Children’s Emergency Fund) is a global organisation that works to protect the health and well-being of children around the world. It provides vaccines, food, education and emergency help in different countries, especially in poor or crisis-affected areas. One of its main goals is to ensure every child gets the healthcare they need, including life-saving vaccines like the one ordered from Panacea Biotec.

Read More: Panacea Biotech Shares Fall 5% Despite Bombay HC Ruling Out 18% GST on Leasehold Land

Share Price Performance 

As of April 24, 2025, at 9:40 AM, Panacea Biotec share price is trading at ₹525.95 per share, reflecting a surge of 2.53% from the previous day’s closing price. Over the past month, the stock has surged by 19.06%. The stock’s 52-week high stands at ₹549.05 per share, while its low is ₹112.35 per share.

Conclusion

This new order highlights Panacea Biotec’s continued role in global health initiatives. The company remains committed to supporting international efforts like UNICEF’s polio vaccination program.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.